Concepedia

Terrill K. McClanahan

TK

Statistics

Publications

83

Citations

38.7K

H-Index

58

Active since

1984

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Institut de Biologie Moléculaire et Cellulaire

FX Palo Alto Laboratory

Palo Alto University

CTI BioPharma (Italy)

Terrill K. McClanahan is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in immunology, life sciences, and inflammation.

Publications per year

1984–2022

83

Publications

83

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

Claire L. Langrish, Yi Chen, Wendy M. Blumenschein et al. · The Journal of Experimental Medicine · 2005 · 4K citations · Full text

Life Sciences, Cell Biology, Immunology +17

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers, Jared Lunceford, Michael Nebozhyn et al. · Journal of Clinical Investigation · 2017 · 3.9K citations · Full text

Medicine, Immunology, Oncology +17

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Răzvan Cristescu, Robin Mogg, Mark Ayers et al. · Science · 2018 · 2.3K citations

Medicine, Immunology, Oncology +17

Development, cytokine profile and function of human interleukin 17–producing helper T cells

Nicholas J. Wilson, Katia Boniface, Jason R. Chan et al. · Nature Immunology · 2007 · 2K citations

Life Sciences, Cell Biology, Immunology +14

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra et al. · The Lancet Oncology · 2016 · 1.7K citations

Medicine, Oncology, Pharmacotherapy +13

1–5 of 83